BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 28577731)

  • 1. Thrombotic microangiopathies and antineoplastic agents.
    Grangé S; Coppo P;
    Nephrol Ther; 2017 Apr; 13 Suppl 1():S109-S113. PubMed ID: 28577731
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Secondary thrombotic microangiopathies].
    Coppo P;
    Rev Med Interne; 2017 Nov; 38(11):731-736. PubMed ID: 28890263
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antineoplastic agents and thrombotic microangiopathy.
    Garcia G; Atallah JP
    J Oncol Pharm Pract; 2017 Mar; 23(2):135-142. PubMed ID: 26854265
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-VEGF-related thrombotic microangiopathy in a child presenting with nephrotic syndrome.
    Yılmaz S; Özçakar ZB; Taktak A; Kiremitçi S; Ensari A; Dinçaslan H; Yalçınkaya F
    Pediatr Nephrol; 2016 Jun; 31(6):1029-32. PubMed ID: 26928310
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Thrombotic Microangiopathy in a Patient Treated With Gemcitabine.
    Nanjappa S; Singh V; Uttamchandani S; Pabbathi S
    Cancer Control; 2017 Jan; 24(1):54-56. PubMed ID: 28178713
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Thrombotic microangiopathy, cancer, and cancer drugs.
    Izzedine H; Perazella MA
    Am J Kidney Dis; 2015 Nov; 66(5):857-68. PubMed ID: 25943718
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An overview of thrombotic complications of old and new anticancer drugs.
    Levi M; Sivapalaratnam S
    Thromb Res; 2020 Jul; 191 Suppl 1():S17-S21. PubMed ID: 32736772
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Thrombotic microangiopathy syndromes.
    Zakarija A
    Cancer Treat Res; 2009; 148():115-36. PubMed ID: 19377922
    [No Abstract]   [Full Text] [Related]  

  • 9. Gemcitabine-related thrombotic microangiopathy: a single-centre retrospective series.
    Leal F; Macedo LT; Carvalheira JB
    J Chemother; 2014 Jun; 26(3):169-72. PubMed ID: 24091354
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bevacizumab-associated thrombotic microangiopathy treated with eculizumab: A case series and systematic review of the literature.
    Hilburg R; Geara AS; Qiu MK; Palmer MB; Chiang EY; Burger RA; Hogan JJ
    Clin Nephrol; 2021 Jul; 96(1):51-59. PubMed ID: 33896447
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Influenza-induced thrombotic microangiopathy in a patient with cancer on proteasome inhibitor: a diagnostic dilemma.
    Hamad CD; Hoelscher ZC; Tchakarov A; Kala J
    CEN Case Rep; 2022 Aug; 11(3):321-327. PubMed ID: 34997535
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sunitinib-induced thrombotic microangiopathy.
    Noronha V; Punatar S; Joshi A; Desphande RV; Prabhash K
    J Cancer Res Ther; 2016; 12(1):6-11. PubMed ID: 27072203
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Thrombotic microangiopathy and cancer].
    Kheder El-Fekih R; Deltombe C; Izzedine H
    Nephrol Ther; 2017 Nov; 13(6):439-447. PubMed ID: 28774729
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Thrombotic microangiopathy associated with gemcitabine use: Presentation and outcome in a national French retrospective cohort.
    Daviet F; Rouby F; Poullin P; Moussi-Francès J; Sallée M; Burtey S; Mancini J; Duffaud F; Sabatier R; Pourroy B; Grandvuillemin A; Grange S; Frémeaux-Bacchi V; Coppo P; Micallef J; Jourde-Chiche N
    Br J Clin Pharmacol; 2019 Feb; 85(2):403-412. PubMed ID: 30394581
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biology of anti-angiogenic therapy-induced thrombotic microangiopathy.
    Eremina V; Quaggin SE
    Semin Nephrol; 2010 Nov; 30(6):582-90. PubMed ID: 21146123
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Frequency and characteristics of chemotherapy-associated thrombotic microangiopathy: Analysis from a large pharmacovigilance database.
    Klomjit N; Evans R; Le TK; Wells SL; Ortega J; Green-Lingren O; Mazepa M; Sise ME; Jhaveri KD; Gupta S
    Am J Hematol; 2023 Dec; 98(12):E369-E372. PubMed ID: 37740927
    [TBL] [Abstract][Full Text] [Related]  

  • 17. C5 inhibition allows continued antineoplastic therapy in cancer- and chemotherapy-associated thrombotic microangiopathy.
    Shah H; Chen H; Pan XZ; Metjian A; Brodsky RA; Braunstein EM; Chaturvedi S
    Blood Adv; 2022 Dec; 6(23):6071-6074. PubMed ID: 35914225
    [No Abstract]   [Full Text] [Related]  

  • 18. Sunitinib-associated thrombotic microangiopathy: a significant risk.
    Buckley FD; Preston G; Meiklejohn DJ; Adamson D
    Clin Oncol (R Coll Radiol); 2014 Aug; 26(8):515. PubMed ID: 24746506
    [No Abstract]   [Full Text] [Related]  

  • 19. Drug-associated thrombotic microangiopathies.
    Kreuter J; Winters JL
    Semin Thromb Hemost; 2012 Nov; 38(8):839-44. PubMed ID: 23037985
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinicopathological spectrum of kidney diseases in cancer patients treated with vascular endothelial growth factor inhibitors: a report of 5 cases and review of literature.
    Usui J; Glezerman IG; Salvatore SP; Chandran CB; Flombaum CD; Seshan SV
    Hum Pathol; 2014 Sep; 45(9):1918-27. PubMed ID: 25087655
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.